Background: Hypovitaminosis D has been cross-sectionally associated with dementia and stroke. The objective of this longitudinal study was to determine whether serum vitamin D deficiency at baseline could predict the onset of non-Alzheimer dementias (NAD) within 7 years among older women. Methods: Forty high-functioning older women (78.4 years, 76.4/82.0; median, 25th/75th percentile) from the EPIDOS Toulouse study were divided into two groups based on vitamin D deficiency (i.e., serum 25-hydroxyvitamin D <10 ng/ml) at baseline. At the end of the 7-year follow-up period, women matching the DSM-IV but not the NINCDS-ADRDA criteria were diagnosed with NAD while those matching the NINCDS-ADRDA criteria were considered to have Alzheimer’s disease (AD). Subtle cognitive impairments at baseline, cardiovascular risk factors and Parkinson’s disease were used as potential confounders. Results: NAD was reported in 6 women (82.8 years, 80.6/86.0) after 7 years of follow-up. More NAD were observed in women with vitamin D deficiency (p = 0.023). There was no between-group difference regarding the onset of AD (p = 0.332). We found an association between vitamin D deficiency at baseline and the onset of NAD (adjusted odds ratio = 19.57, p = 0.042). Conversely, vitamin D deficiency was not associated with AD (p = 0.222). Conclusion: Baseline vitamin D deficiency predicted the onset of NAD within 7 years among older women.

Keywords:
Vitamin D, Dementia, Older adults, Longitudinal study
1.
Annweiler C, Souberbielle JC, Schott AM, de Decker L, Berrut G, Beauchet O: Vitamin D in the elderly: 5 points to remember (in French). Geriatr Psychol Neuropsychiatr Vieil 2011;9:259–267.
2.
Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, Kressig RW, Beauchet O: Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 2009;16:1083–1089.
3.
Oudshoorn C, Mattace-Raso FU, van der Velde N, Colin EM, van der Cammen TJ: Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008;25:539–543.
4.
Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, Ferrucci L, Melzer D: Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010;170:1135–1141.
5.
Annweiler C, Schott AM, Allali G, Bridenbaugh SA, Kressig RW, Allain P, Herrmann FR, Beauchet O: Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology 2010;74:27–32.
6.
Annweiler C, Fantino B, Le Gall D, Schott AM, Berrut G, Beauchet O: Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. J Am Geriatr Soc 2011;59:169–171.
7.
Buell JS, Dawson-Hughes B, Scott TM, Weiner DE, Dallal GE, Qui WQ, Bergethon P, Rosenberg IH, Folstein MF, Patz S, Bhadelia RA, Tucker KL: 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010;74:18–26.
8.
Kalueff AV, Tuohimaa P: Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care 2007;10:12–19.
9.
Annweiler C, Schott AM, Berrut G, Chauvire V, Le Gall D, Inzitari M, Beauchet O: Vitamin D and ageing: neurological issues. Neuropsychobiology 2010;62:139–150.
10.
Wang Y, Chiang YH, Su TP, Hayashi T, Morales M, Hoffer BJ, Lin SZ: Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000;39:873–880.
11.
Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Bréart G: Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145–149.
12.
Annweiler C, Schott AM, Montero-Odasso M, Berrut G, Fantino B, Herrmann FR, Beauchet O: Cross-sectional association between serum vitamin D concentration and walking speed measured at usual and fast pace among older women: the EPIDOS study. J Bone Miner Res 2010;25:1858–1866.
13.
Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish E, Ousset PJ, Albarede JL, Vellas B, Grandjean H; EPIDOS study: Association of Alzheimer’s disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003;58:372–377.
14.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
15.
Tucker GJ: The diagnosis of delirium and DSM-IV. Dement Geriatr Cogn Disord 1999;10:359–363.
16.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
17.
Hogervorst E, Barnetson L, Jbst KA, Nagy Z, Combrinck M, Smith AD: Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer’s disease. Dement Geriatr Cogn Disord 2000;11:107–113.
18.
Reijmer YD, van den Berg E, van Sonsbeek, Dekker JM, Nijpels G, Stehouwer CD, Kappelle JL, Biessels G: Dementia risk score predicts cognitive impairment after a period of 15 years in a nondemented population. Dement Geriatr Cogn Disord 2011;31:152–157.
19.
Pfeiffer E: A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23:433–441.
20.
Erkinjuntti T, Sulkava R, Wikstrom J, Autio L: Short Portable Mental Status Questionnaire as a screening test for dementia and delirium among the elderly. J Am Geriatr Soc 1987;35:412–416.
21.
Lakatta EG: Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 2002;7:29–49.
22.
Klimkowicz A, Dziedzic T, Slowik A, Szczudlik A: Incidence of pre- and post-stroke dementia: Cracow stroke registry. Dement Geriatr Cogn Disord 2002;14:137–140.
23.
Yaffe K, Middleton LE, Lui LY, Spira AP, Stone K, Racine C, Ensrud KE, Kramer JH: Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch Neurol 2011;68:631–636.
24.
National Heart Lung and Blood Institute: Clinical Guideline on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. 1998.
25.
Johnson DK, Galvin JE: Longitudinal changes in cognition in Parkinson’s disease with and without dementia. Dement Geriatr Cogn Disord 2011;31:98–108.
26.
Sato Y, Kikuyama M, Oizumi K: High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997;49:1273–1278.
27.
Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V: Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008;65:1348–1352.
28.
Smith MP, Fletcher-Turner A, Yurek DM, Cass WA: Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res 2006;31:533–539.
29.
Derex L, Trouillas P: Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disord 1997;12:612–613.
30.
Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P: Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008;28:1179–1185.
31.
Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N: 25-Hydroxyvitamin D3–1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005;111:1666–1671.
32.
Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063–1069.
33.
Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633–1637.
34.
Brown J, Bianco JI, McGrath JJ, Eyles DW: 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003;343:139–143.
35.
Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwickie M, Cashman J, Fiala M: 1alpha,25-Dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2009;17:703–717.
36.
Yu J, Gattoni-Celli M, Zhu H, Bhat NR, Sambamurti K, Gattoni-Celli S, Kindy MS: Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J Alzheimers Dis 2011;25:295–307.
37.
Annweiler C, Beauchet O: Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology 2011;37:249–258.
38.
Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O: Alzheimer’s disease – input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials 2011;12:230.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.